Postępy Psychiatrii i Neurologii
2/2026 vol. 35
Opis przypadku

Polypharmacy’s paradox: accelerated decline in a rare case of Lafora body disease

Tasneem Hussain 1
,
Krishna Gupta 1
,
Ashutosh Tiwari 1
,
Pooja S. Mishra 1
  1. Mahatma Gandhi Memorial Medical College and M.Y. Hospital, Indore, M.P., India
Adv Psychiatry Neurol 2026; 35 (2): 141-145
DOI: https://doi.org/10.5114/ppn.2026.161380
Data publikacji online: 2026/05/13
Plik artykułu
PPiN-00555-Polypharmacy.pdf
Confronting perimenopausal women’s knowledge of coronary heart disease with their health behaviours. Controversial role of hormone replacement therapy in the protection of coronary heart disease
  1. Turnbull J, Tiberia E, Striano P, Genton P, Carpenter S, Ackerley CA, Minassian BA. Lafora disease. Epileptic Disord 2016; 18 (S2): 38-62.
  2. Ibrahim F, Murr NI. Lafora Disease. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025.
  3. Cameron JM, Ellis CA, Berkovic SF. Progressive myoclonus epilepsies. Epileptic Disord 2023; 25: 670-680.
  4. Ong LC. Seizures exacerbated by antiepileptic drugs in children. Neurology Asia 2010; 15 (Suppl 1): 11-12.
  5. Brodie MJ, Besag F, Ettinger AB, Mula M, Gobbi G, Comai S, et al. Epilepsy, antiepileptic drugs, and aggression: an evidence-based review. Pharmacol Rev 2016; 68: 563-602.
  6. Genton P. When antiepileptic drugs aggravate epilepsy. Brain Dev 2000; 22: 75-80.
  7. Perucca E. Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol 2006; 61: 246-255.
  8. Guerrini R, Belmonte A, Genton P. Antiepileptic drug-induced worsening of seizures in children. Epilepsia 1998; 39 Suppl 3: S2-S10.
  9. Duran J. Role of astrocytes in the pathophysiology of Lafora disease and other glycogen storage disorders. Cells 2023; 12: 722. DOI: 10.3390/cells12050722.
  10. Bisulli F, Muccioli L, d’Orsi G, Canafoglia L, Freri E, Licchetta L, et al. Treatment with metformin in twelve patients with Lafora disease. Orphanet J Rare Dis 2019; 14: 149. DOI: 10.1186/s13023-019-1132-3.
  11. Burgos DF, Machío-Castello M, Iglesias-Cabeza N, Giráldez BG, González-Fernández J, Sánchez-Martín G, et al. Early treatment with metformin improves neurological outcomes in Lafora disease. Neurotherapeutics 2023; 20: 230-244.
  12. Maini DK, Gupta D, Saran RK, Dua A, Rehani V, Anand R. Use of cannabidiol in the management of refractory seizures in Lafora disease: a case report of two siblings. J Clin Images Med Case Rep 2025; 6: 3694. DOI: 10.52768/2766-7820/3694.
  13. Aso E, Andrés-Benito P, Grau-Escolano J, Caltana L, Brusco A, Sanz P, Ferrer I. Cannabidiol-enriched extract reduced the cognitive impairment but not the epileptic seizures in a Lafora disease animal model. Cannabis Cannabinoid Res 2020; 5: 150-163.
  14. Ahonen S, Nitschke S, Grossman TR, Kordasiewicz H, Wang P, Zhao X, et al. Gys1 antisense therapy rescues neuropathological bases of murine Lafora disease. Brain 2021; 144: 2985-2993.
  15. d’Orsi G, Liantonio A, Imbrici P, Gambacorta N, Dinoi G, Altomare CD; DEFEAT-LD Study Group. Empagliflozin repurposing for Lafora disease: a pilot clinical trial and preclinical investigation of novel therapeutic targets. Methods Protoc 2025; 8: 48. DOI: 10.3390/mps8030048.
  16. Muccioli L, Vignatelli L, Tappatà M, Mazzone S, Zenesini C, Armstrong D; DEFEAT-LD Study Group. VAL-1221 for the treatment of patients with Lafora disease: study protocol for a single-arm, open-label clinical trial. BMJ Open 2024; 14: e085062. DOI: 10.1136/bmjopen-2024-085062.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0). License allowing third parties to download and share its works but not commercially purposes or to create derivative works.
Udostępnij
without publication fees
Dostępne w
Indeksowane w
pubmed
Zintergrowane z
Zasady redakcyjne
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications